Diastolic Heart Failure: Evidence of Increased Myocardial Collagen Turnover Linked to Diastolic Dysfunction

Background— The pathophysiology of diastolic heart failure (DHF) is poorly understood. One potential explanation is an active fibrotic process that produces increased ventricular stiffness, which compromises filling. The present study investigates collagen metabolism in hypertensive patients in different phases of diastolic function with and without proven DHF. Methods and Results— We studied 86 hypertensive patients divided into groups according to the presence of DHF (32 with, 54 without) and phase of diastolic function (20 with normal function, 38 with impaired relaxation, 10 with pseudonormalization, and 16 with restrictive-like filling). Serum carboxy-terminal, amino-terminal, and carboxy-terminal telopeptide of procollagen type I, amino-terminal propeptide of procollagen type III, matrix metalloproteinases (MMPs; total MMP-1, active MMP-2, and MMP-9), and tissue inhibitor of MMPs levels were assayed by radioimmunoassay and ELISA. Doppler-echocardiographic assessment of diastolic filling was made with measurements of E/A ratio, E-wave deceleration time, and isovolumic relaxation time. Serum carboxy-terminal telopeptide of procollagen type I, carboxy-terminal telopeptide of procollagen type I, amino-terminal propeptide of procollagen type III, MMP-2, and MMP-9 levels (P<0.001 for all, controlled for age and gender) were greater in patients with DHF than in those without. When we controlled for age and gender, levels of serum carboxy-terminal telopeptide of procollagen type I, tissue inhibitor of MMP-1, amino-terminal propeptide of procollagen type III (all P<0.001), carboxy-terminal telopeptide of procollagen type I(P=0.008), and MMP-2 (P=0.03) were greater in more severe phases of diastolic dysfunction. Within phases of diastolic dysfunction, serum carboxy-terminal telopeptide of procollagen type I, amino-terminal propeptide of procollagen type III, MMP-2, and MMP-9 were elevated in those with DHF compared with those without DHF (all P<0.001). Conclusions— These data demonstrate serological evidence of an active fibrotic process in DHF, which is more marked in more severe diastolic dysfunction. This observation may help explain the pathophysiology of DHF and may suggest new avenues for diagnostic and therapeutic intervention.

[1]  K. Weber,et al.  Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. , 1996, Hypertension.

[2]  J. Díez,et al.  Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. , 1996, Circulation.

[3]  B. Strauer,et al.  Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. , 2000, Hypertension.

[4]  G. Asboe-hansen.  Connective tissue : in health and disease , 1954 .

[5]  N. Tamura,et al.  Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. , 2001, Canadian journal of physiology and pharmacology.

[6]  F. Alla,et al.  Early changes in serum markers of cardiac extra‐cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes , 2006, European journal of heart failure.

[7]  Arantxa González,et al.  Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients , 2002, Circulation.

[8]  A. D'Angelo,et al.  Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. , 2006, Endothelium : journal of endothelial cell research.

[9]  A. DeMaria,et al.  Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction , 2002 .

[10]  A. DeMaria,et al.  Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction: Comparison With Doppler Velocity Recordings , 2002, Circulation.

[11]  Arantxa González,et al.  Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. , 2006, Journal of the American College of Cardiology.

[12]  G. Aurigemma,et al.  Left Ventricular Systolic Performance, Function, and Contractility in Patients With Diastolic Heart Failure , 2005, Circulation.

[13]  Yasmin,et al.  Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity Are Associated With Systolic Hypertension and Arterial Stiffness , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[14]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[15]  F. Magrini,et al.  Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. , 1997, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[16]  Arantxa González,et al.  Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin: Relation to Myocardial Fibrosis , 2004, Circulation.

[17]  K. Swedberg,et al.  Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. , 2004, Journal of the American College of Cardiology.

[18]  M. Senni,et al.  Heart failure with preserved systolic function. A different natural history? , 2001, Journal of the American College of Cardiology.

[19]  M. Chiariello,et al.  Myocardial Collagen Turnover in Hypertrophic Cardiomyopathy , 2003, Circulation.

[20]  F. Dunn,et al.  TIMP-1: A Marker of Left Ventricular Diastolic Dysfunction and Fibrosis in Hypertension , 2002, Hypertension.

[21]  J. Seward,et al.  Left Atrial Volume: A Powerful Predictor of Survival After Acute Myocardial Infarction , 2003, Circulation.

[22]  Arantxa González,et al.  Biochemical assessment of myocardial fibrosis in hypertensive heart disease. , 2001, Hypertension.

[23]  K. Sunagawa,et al.  Targeted Deletion of Matrix Metalloproteinase 2 Ameliorates Myocardial Remodeling in Mice With Chronic Pressure Overload , 2006, Hypertension.

[24]  M A Rossi,et al.  Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans , 1998, Journal of hypertension.

[25]  C. Brilla,et al.  Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease , 2000, Circulation.

[26]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[27]  A. Tajik,et al.  Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. , 2006, Journal of the American College of Cardiology.

[28]  Leslie L. Clark,et al.  Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease , 2006, Circulation.

[29]  J. Emparanza,et al.  Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. , 2000, Circulation.

[30]  Arantxa González,et al.  Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. , 2004, Journal of the American College of Cardiology.

[31]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[32]  W. Gaasch,et al.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. , 2004, The New England journal of medicine.

[33]  K. Nakao,et al.  Inhibitory Effect of Natriuretic Peptides on Aldosterone Synthase Gene Expression in Cultured Neonatal Rat Cardiocytes , 2003, Circulation.

[34]  T. Marwick,et al.  Effect of Aldosterone Antagonism on Myocardial Dysfunction in Hypertensive Patients With Diastolic Heart Failure , 2004, Circulation.